GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » Gross Margin %

GlycoNex (ROCO:4168) Gross Margin % : 60.87% (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is GlycoNex Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. GlycoNex's Gross Profit for the three months ended in Mar. 2024 was NT$5.62 Mil. GlycoNex's Revenue for the three months ended in Mar. 2024 was NT$9.24 Mil. Therefore, GlycoNex's Gross Margin % for the quarter that ended in Mar. 2024 was 60.87%.


The historical rank and industry rank for GlycoNex's Gross Margin % or its related term are showing as below:

ROCO:4168' s Gross Margin % Range Over the Past 10 Years
Min: 20.3   Med: 49.08   Max: 98.2
Current: 56.98


During the past 13 years, the highest Gross Margin % of GlycoNex was 98.20%. The lowest was 20.30%. And the median was 49.08%.

ROCO:4168's Gross Margin % is ranked worse than
53.33% of 750 companies
in the Biotechnology industry
Industry Median: 60.53 vs ROCO:4168: 56.98

GlycoNex had a gross margin of 60.87% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for GlycoNex was 5.70% per year.


GlycoNex Gross Margin % Historical Data

The historical data trend for GlycoNex's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoNex Gross Margin % Chart

GlycoNex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.30 27.72 63.21 46.43 39.14

GlycoNex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.95 33.03 54.66 - 60.87

Competitive Comparison of GlycoNex's Gross Margin %

For the Biotechnology subindustry, GlycoNex's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoNex's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoNex's Gross Margin % distribution charts can be found below:

* The bar in red indicates where GlycoNex's Gross Margin % falls into.



GlycoNex Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

GlycoNex's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=1 / 2.542
=(Revenue - Cost of Goods Sold) / Revenue
=(2.542 - 1.547) / 2.542
=39.14 %

GlycoNex's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=5.6 / 9.238
=(Revenue - Cost of Goods Sold) / Revenue
=(9.238 - 3.615) / 9.238
=60.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


GlycoNex  (ROCO:4168) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

GlycoNex had a gross margin of 60.87% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


GlycoNex Gross Margin % Related Terms

Thank you for viewing the detailed overview of GlycoNex's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoNex (ROCO:4168) Business Description

Traded in Other Exchanges
N/A
Address
Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies which targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability and can serve as reagent with applications that include ELISA, Western blot, flow cytometry, TLC immunostaining, and IHC. The group also provides antibody research service to its academic and industrial clients. The other services provided by the firm include functional evaluation, antibody engineering, and antibody characterization.

GlycoNex (ROCO:4168) Headlines

No Headlines